

Gordon Dunn Report—September 2019

1. Statin use and longitudinal changes in prostate volume; results from the REDUCE trial.

<https://www.ncbi.nlm.nih.gov/pubmed/31479563>

2. Systematic biopsy does not contribute to disease upgrading in patients undergoing targeted biopsy for PI-RADS 5 lesions identified on magnetic resonance imaging in the course of active surveillance for prostate cancer.

<https://www.ncbi.nlm.nih.gov/pubmed/31479660>

3. FDA Approves Bayer's Nubeqa® (darolutamide), a New Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer

<https://www.pcf.org/news/fda-approves-bayers-nubeqa-darolutamide-a-new-treatment-for-men-with-non-metastatic-castration-resistant-prostate-cancer/>

<https://www.nejm.org/doi/full/10.1056/NEJMoa1815671>